Browsing Tag
RECLAIM
1 post
Altimmune’s $535m balance sheet backs new pemvidutide alcohol use disorder pathway
Pemvidutide reduced heavy drinking in Phase 2, opening a new market for Altimmune as investors weigh cash, dilution and Phase 3 risks.